Following heart and cancer diseases, accidental trauma is the leading cause of death for children and young adults in developed countries. Central nervous system (CNS) lesions cause working incapacity and chronic disability and often occur in individuals below the age of 45 years. Although the outcome of brain or spinal cord injuries depends on the damaged area and the extent of the injury, currently available therapies that can only provide symptoms relief and rehabilitation.

After spinal cord injury (SCI), a dynamic series of cellular and molecular events take place in the affected zone. While blood phagocytes remove cellular debris and secondary neuronal death progresses, neural stem cells migrate near the damaged zone, proliferate and differentiate to astrocytes that enlarge their fibrous processes, forming a glial boundary between the injured area and the uninjured CNS. Fibroblasts from adjacent connective tissue divide and overlay the fibrous astrocytes, depositing collagen, thus completing the formation of the new CNS boundary, called the glial scar, where cells of the scar, mainly reactive astrocytes, reactive microglia, pericytes, fibroblasts and extracellular matrix, make the glial scar a hostile environment for axonal growth. Astrocytes and microglia represent highly reactive CNS cell populations and their principal role in glia scarring has been well documented elsewhere.

The astrocyte response to CNS injury is also characterized by the production of chondroitin sulfate proteoglycans (CSPGs), which present a potent barrier to axon regeneration. The inhibitory action of CSPGs has been attributed to the abundance of negatively charged glycosaminoglycan (GAG) chains that decorate the protein core, which are thought to act as a poor substrate and electrostatically repel growth cones. Protein tyrosine phosphatase sigma (PTPsigma), leukocyte common antigen related phosphatase (LAR) and Nogo receptor (NgR) have been identified as neuronal receptors that functionally interact with and mediate CSPG-dependent inhibition of neuronal growth. Chondroitinase ABC (chABC), a bacterial enzyme that digests the GAG chains, abolishes CSPG-dependent neurite outgrowth inhibition *in vitro* and improves neurite outgrowth and functional recovery after SCI. Therefore pharmacological targeting of CSPG receptors is a strategy to relieve CSPG-dependent capture of growth cones that has shown some potential. While these studies have identified CSPG receptors as possible targets, future work should focus on developing small molecule inhibitors to achieve better CNS penetration and distribution for earlier and more efficient targeting after injury (Kaplan et al., 2015). In this sense, we consider the design and synthesis of glycoside inhibitors to achieve specific and temporal inhibition of astroglia. This, in turn, would permit a significant reduction of CSPGs production, promote axonal growth and functional recovery of neurons and glial cells (Doncel-Perez et al., 2013; Garcia-Alvarez et al., 2015).

CNS myelin derivatives constitute a barrier to axon regeneration at sites of injury. The different types of CNS neurons possess very different regenerative capacities, and specific mechanisms for myelin inhibition related to neuron-type must be considered. But in general, myelin-associated inhibitors (MAIs) including Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp) collapse axonal growth cones and inhibit growth. Targeting these external inhibitory factors has led to some improvements in axonal plasticity and functional recovery after CNS injury. In addition, stimulating intrinsic growth potential by neuronal knockout of negative regulators of growth, including phosphatase and tensin homolog (PTEN) and suppressor of cytokine signaling 3 (SOCS3), can induce striking long-distance axon regeneration after CNS injury (Sun et al., 2011). Furthermore, engraftment of neural stem cells into transected rodent spinal cords can result in impressive long-distance growth of grafted cells (Lu et al., 2012). These studies indicate that an increased intrinsic neuronal growth potential is able to overcome the inhibitory nature of the injured CNS.

The actin-regulating small GTPase RhoA and downstream effector Rho kinase (ROCK), are extensively studied mediators of neurite outgrowth inhibition in the CNS. MAIs have been shown to increase the levels of active GTP-bound RhoA. Inhibition of ROCK, stimulates neurite outgrowth on myelin and infusion of small molecule ROCK inhibitors Y-27632 or fasudil into the injured rat spinal cord improves locomotor recovery. RhoA can be specifically inhibited with *Clostridium botulinum* exoenzyme C3 transferase, which ADP-ribosylates and inactivates RhoA. Treatment of animals with C3 improves locomotor recovery in contusion and dorsal hemisection injury models. The positive outcomes with C3 have translated into a phase I/II clinical trial with Cethrin (BA-210), a cell-permeable form of C3 that is delivered locally over the dura mater in a fibrin sealant during spinal surgery (Lord-Fontaine et al., 2008; Kaplan et al., 2015).

The ability of implanted neural stem cells (NSCs) to survive and functionally integrate into injured host spinal cord in rodents, also suggests that the inhibitory nature of the injured CNS can be overcome by neurons with vigorous growth capacity. NSCs have been shown to extend long axons throughout the grey and white matter of transected host spinal cords, establishing an electrophysiological bridge across the injury (Lu et al., 2012). Grafted NSCs had the ability to integrate into the host spinal cords, but it was also noted the presence of ectopic colonies of donor cells throughout the spinal cord and brain stem in half of the animals (Steward et al., 2014). This highlights the caution that must be exercised in the development of NSC therapies, as implanted cells may give rise to tumors, and exuberant synaptic connections could result in unfavorable behavioral and sensory side effects, including neuropathic pain. Anyway, the experiments provided proof that neurons from NSCs with high growth capacity were capable of extensive growth in the injured CNS, in spite of the presence of inhibitory factors.

An approach in SCI therapy is the modulation of cellular and molecular process involved in glial scarring. It contains two main elements: i) supporting, preserving and promoting axonal growth of resident and new neurons, and ii) inhibiting glial activation and glial scar formation (**[Figure 1](#F1){ref-type="fig"}**).
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After SCI, the astrocytes near the damaged zone proliferate, enlarge their fibrous processes, produce CSPGs and form a glial scar in the spinal cord, and a cystic cavity. All these interrupt neuronal tracts and provoke axonal retraction in injured neurons. In addition, CNS myelin debris from damaged axons generates MAIs, MAG and OMgp, that inhibits axonal growth and induces neuronal death (Panel A). The administration of RhoGTPase inhibitor reduces the size and inhibits reactive astrocytes and their production of CSPGs. The injection of NSCs, as neurospheres, differentiates them to aldaynoglia, which promotes axonal growth, re-myelination and the re-connection of nerve tracts by interneurons generated *de novo* from transplanted or resident neural precursors (Panel B). CNS: Central nervous system; CSPGs: chondroitin sulfate proteoglycans; MAIs: myelin-associated inhibitors; MAG: myelin-associated glycoprotein; NSCs: neural stem cells; OMgp: oligodendrocyte myelin glycoprotein; SCI: spinal cord injury.](NRR-11-1043-g001){#F1}

Regarding the first process we obtained aldynoglia, which are growth-promoting glial cells existing in olfactory bulb, hypothalamus, hypophysis and pineal gland, that share with Schwann cells (SCs) the ability to survive and proliferate in culture, to promote neurite outgrowth, and to ensheath and myelinate neurites. The cells typical of these CNS loci, olfactory ensheathing cells (OECs), tanycytes, pituicytes, and pineal interstitial cells, may be identified in culture by their concomitantly expressing a set immunological markers, namely peripheral GFAP, vimentin, p75 NGF receptor, and type α estrogen receptor, showing a mixture of SC-like and astrocyte-like properties. Transplants of aldynoglia have considerable potential for the treatment of CNS injuries. Multipotent NSCs can be isolated from various mammalian CNS regions at different stages of development and cultured as floating neurospheres. Given the appropriate signals, neurosphere cells can differentiate *in vitro* to neurons, astrocytes, and oligodendrocytes, although their behavior when transplanted is more variable. Rodent neurospheres when transplanted differentiated predominantly to glia, whereas grafts of human embryonic forebrain neurospheres also gave rise to a significant proportion of neurons. We reported that mesencephalic rodent neurospheres differentiated *in vitro* predominantly to cells with properties similar to aldynoglia, when exposed to OEC-conditioned medium (OEC-CM), This contains a mixture of neurotrophins (NGF, BDNF) and neuregulins, apparently capable of instructing neurospheres to develop into neural progenitors with aldynoglia phenotype. The OEC-CM caused neurosphere cells to differentiate to cells with peripheral glia phenotype, as judged by their expression of mRNA and protein markers (GFAP, vimentin, nestin, and S100 proteins). Neurosphere cells, when co-cultured with dorsal root ganglia (DRG), migrated towards the ganglia, invaded them and contacted DRG neurons. Direct aldaynoglia-neuron interaction was necessary and sufficient to promote neurite outgrowth, ensheathment, and myelination (Doncel-Perez et al., 2009). The possibility of differentiating neurosphere cells to aldynoglia could satisfy the necessity of the great amount of cells in cell transplants required to repair large CNS injuries.

To cover the second process, we tried to inhibit glial cells in a specific manner, while avoiding to affect other neural cell types, *i.e*., neurons and oligodendrocytes. Over the last years, based on the chemical structure of a natural inhibitor of astroblast and astrocytoma division (neurostatin), we analyzed glycosides as inhibitors of glioma division. Among the compounds tested, sulphated glycolipids presented the highest inhibitory activity for human and rat glioma division. Interestingly, the use of DNA microarray technology revealed that the ARHGDIA gene was repressed. The product of this gene is Rho guanine nucleotide dissociation inhibitor alpha (RhoGDIα), a regulator of RhoGTPases (Doncel-Perez et al., 2013; Garcia-Alvarez et al., 2015). We showed recently that the sulfoglycolypid affected glial cells by interacting with the RhoGDIα protein, causing an increase in the expression of TrkB genes in neural cells, myelin production by oligodendrocytes and promoting axonal growth from DRG neurons. The astroglial cells changed their morphology and this was mainly transduced by the BDNF/TrkBT1/RhoGDIα pathway, which is also operative in microglia. The TrkT1 isoform corresponds to the TrkB truncated form of the receptor with a short cytoplasmic domain of 11 amino acid residues in the C-terminus. This domain interacts with RhoGDIα inducing influx of Ca^2+^ and morphological change in glia cells. The inhibition of the pathway BDNF/TrkB/RhoGDIα in astrocytes and microglial cells, by sequestering RhoGDIα, was proposed as a new target for SCI therapy (Garcia-Alvarez et al., 2015).

Above we mentioned that grafted NSCs could integrate into host spinal cords and brain, but implanted cells may give rise to tumors and neuropathic pain. Here we propose that a combination of NSCs and antiproliferative glycoside could save this obstacle (**[Figure 1](#F1){ref-type="fig"}**). The antiproliferative properties of the compound diminished the risk of tumor growth (Doncel-Perez et al., 2013) and could facilitate the movement of transplanted NSCs in a less rigid environment by glial laxity.

The axonal growth promotion by aldaynoglia and the inhibition of RhoGTPase activity in glia cells occurred simultaneously. The presence of sulfoglycolipid potentiated the axon outgrowth induced in DRG neurons, and aldynoglial cells were not affected by the glycoside. This indicates that the inhibition of the activity was due to the anti-proliferative effect of the glycoside and did not affect other functions in aldaynoglia. The astrocyte recruitment after injury relies on proliferation and the number of astrocytes recruited to a CNS lesion site is significantly reduced in RhoGTPase deficient mice. In other scenarios, high RhoGTPase activity in aged hematopoietic stem cells (HSC) was causally linked to HSC aging and correlated with a loss of polarity in aged HSCs, and pharmacological inhibition of RhoGTPase Cdc42 activity functionally rejuvenated aged HSCs, increased the proportion of polarized cells in aged HSC population, and restored the level and spatial distribution of histone acetylation to a status similar to that seen in young HSCs (Florian et al., 2012).

Aldaynoglia cells are neural cell precursors with capacity to differentiate to neurons, promote axonal growth, wrapping and myelination. The selective inhibition of RhoGTPase activity in astroglia and microglia by sulfoglicolipid reduced their cell proliferation, induced retraction of glial cell processes and increased myelin production by oligodendrocytes (Doncel-Perez et al., 2009; Muneton-Gomez et al., 2012; Garcia-Alvarez et al., 2015). These properties are desired for SCI therapy where functional potentiation of neurons and oligodendrocytes results in a better motor recovery. Rats with a moderate spinal cord contusion, treated with spinal injection of sulfoglicolipid, showed a significative recovery (Garcia-Alvarez et al., 2015), which was also seen in a rat model of striatal lacunar infarction, where new neurons derived from aldaynoglia integrated into the CNS host circuitry and establishing synaptic contacts (Muneton-Gomez et al., 2012). These data support the use of aldaynoglia and RhoGTPase inhibitors as useful tools for therapy in CNS trauma, particularly in the SCI treatment.
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